Patents Issued in May 4, 2017
  • Publication number: 20170119752
    Abstract: The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.
    Type: Application
    Filed: January 5, 2017
    Publication date: May 4, 2017
    Applicant: DIGNITY HEALTH
    Inventors: Fu-Dong Shi, Ronald J. Lukas, Timothy Vollmer
  • Publication number: 20170119753
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio RANCATI, Andrea RIZZI, Laura CARZANIGA, Ian LINNEY, Chris KNIGHT, Wolfgang SCHMIDT
  • Publication number: 20170119754
    Abstract: A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 5, 2016
    Publication date: May 4, 2017
    Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
  • Publication number: 20170119755
    Abstract: The present invention provides a pharmaceutical composition comprising naltrexone or an analogue thereof for use in the treatment of a subject having a tumour/cancer; wherein the naltrexone or the analogue thereof is to be administered to the subject in a first treatment phase, followed by a recovery phase; wherein, following the recovery phase, a small molecule signalling inhibitor selected from the group consisting of PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and cell cycle inhibitors is to be administered to the subject in a second treatment phase; the recovery phase being characterised by the absence of administration of the naltrexone or the analogue thereof and the small molecule signalling inhibitor.
    Type: Application
    Filed: June 9, 2015
    Publication date: May 4, 2017
    Inventors: Angus Dalgleish, Wai Liu
  • Publication number: 20170119756
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Inventor: Richard Sackler
  • Publication number: 20170119757
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 4, 2017
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Publication number: 20170119758
    Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene for sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Inventors: Thomas CHEN, Daniel LEVIN, Satish PUPALLI
  • Publication number: 20170119759
    Abstract: There are provided pharmaceutical compositions comprising a compound of Formula (I) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
    Type: Application
    Filed: June 15, 2016
    Publication date: May 4, 2017
    Applicant: AstraZeneca AB
    Inventors: Noel Alan Weldon Baker, Alpesh Mistry
  • Publication number: 20170119760
    Abstract: A mast cell inhibitor, a pharmaceutical composition and a method for treating patients afflicted with Progressive Supranuclear Palsy (PSP), wherein the patients are treated with a tyrosine kinase inhibitor, c-Kit inhibitor or mast cell inhibitor, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170119761
    Abstract: The invention relates to disubstituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives of the general formula (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are such as defined in claim 1, to a method for preparing same, and to the therapeutic use of said compounds.
    Type: Application
    Filed: November 10, 2016
    Publication date: May 4, 2017
    Inventors: Marco BARONI, Letizia PULEO
  • Publication number: 20170119762
    Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
    Type: Application
    Filed: December 9, 2016
    Publication date: May 4, 2017
    Applicant: Biotherapeutics, Inc.
    Inventors: Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
  • Publication number: 20170119763
    Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.
    Type: Application
    Filed: March 26, 2015
    Publication date: May 4, 2017
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Eleonora JOVCHEVA, Timothy Pietro Suren PERERA
  • Publication number: 20170119764
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: November 11, 2016
    Publication date: May 4, 2017
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-Jung Pyun
  • Publication number: 20170119765
    Abstract: 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated with osteoarthritis in the knee.
    Type: Application
    Filed: June 30, 2015
    Publication date: May 4, 2017
    Inventors: Tobias Paehler, Klaus Flechsenhar, Kirsten Grothe, Martin Lunnon, Christelle Jan
  • Publication number: 20170119766
    Abstract: The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Inventors: Bayard R. HUCK, Samantha M. GOODSTAL, Claude GIMMI-MCKIM
  • Publication number: 20170119767
    Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Applicant: Resverlogix Corp.
    Inventor: Narmada R. Shenoy
  • Publication number: 20170119768
    Abstract: Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like.
    Type: Application
    Filed: October 20, 2016
    Publication date: May 4, 2017
    Inventors: Rui HOU, Gen LI
  • Publication number: 20170119769
    Abstract: Disclosed herein are methods and compositions for treating, as well as identifying potential therapeutics for, cancers or diabetes, with compounds that inhibit the activity of menin, preferably the compounds are capable of inhibiting MLL binding to menin.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 4, 2017
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Xianxin HUA, Abdul Bari MUHAMMAD
  • Publication number: 20170119770
    Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: January 9, 2017
    Publication date: May 4, 2017
    Inventors: Shelley Allen, Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Lily Huang, Yutong Jiang, Timothy Kercher, Jeongbeob Seo
  • Publication number: 20170119771
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximah, and ofatumumab.
    Type: Application
    Filed: June 30, 2016
    Publication date: May 4, 2017
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Albert YU, Langdon MILLER, Thomas M. JAHN
  • Publication number: 20170119772
    Abstract: A beverage composition comprising phlorotannin, a ginseng extract and caffeine, and being effective in improving work performance, such as improving concentration and fatigue, preventing sleepiness, relieving hangovers, reducing headaches and improving physical abilities.
    Type: Application
    Filed: August 4, 2016
    Publication date: May 4, 2017
    Inventors: Haeng-Woo LEE, Hyun-Cheol CHEON, Seong-Ho KIM, Hyeon-Cheol SHIN, Ju-Hee KIM, Jae-Keun OH
  • Publication number: 20170119773
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 4, 2017
    Inventors: Thomas FRIEDL, Michael BRAUN, Kenji EGUSA, Hikaru FUJITA, Megumi MARUYAMA, Takaaki NISHIOKA
  • Publication number: 20170119774
    Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
    Type: Application
    Filed: December 7, 2016
    Publication date: May 4, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20170119775
    Abstract: The technology provided herein relates to the novel use of compounds for improving cognition, concentration capacity, learning capacity and/or memory retentiveness, in particularly for the treatment and/or prophylaxis of cognitive, concentration capacity, learning capacity and/or memory retentiveness disorders.
    Type: Application
    Filed: March 20, 2015
    Publication date: May 4, 2017
    Inventors: Guido Koopmans, Birgit Hasse
  • Publication number: 20170119776
    Abstract: The present application relates to novel, chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to a method for their preparation, to their use on their own or in combinations for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diseases of the respiratory tracts, the lung and the cardiovascular system.
    Type: Application
    Filed: March 31, 2015
    Publication date: May 4, 2017
    Inventors: Hartmut BECK, Volkhart Min-Jian LI, Andreas TIMMERMANN, Pamela BOGNER, Yolanda CANCHO GRANDE, Dirk BROHM, Michael GERISCH, Hannah JÖRISSEN, Dieter LANG
  • Publication number: 20170119777
    Abstract: The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents.
    Type: Application
    Filed: December 1, 2016
    Publication date: May 4, 2017
    Applicant: VIIV HEALTHCARE COMPANY
    Inventor: Mark Richard UNDERWOOD
  • Publication number: 20170119778
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 4, 2017
    Inventors: Aranapakam Mudumbai VENKATESAN, Zecheng CHEN, Christoph Martin DEHNHARDT, Osvaldo DOS SANTOS, Efren Guillermo DELOS SANTOS, Arie ZASK, Jeroen Cunera VERHEIJEN, Joshua Aaron KAPLAN, David James RICHARD, Semiramis AYRAL-KALOUSTIAN, Tarek Suhayl MANSOUR, Ariamala GOPALSAMY, Kevin Joseph CURRAN, Mengxiao SHI
  • Publication number: 20170119779
    Abstract: The present invention relates to a method of treating pre-term labour with retosiban in subjects with conditions resulting in uterine overdistension including polyhydroamnios and multiple gestation. In another aspect, the invention relates to a method of preventing pre-term labour in subjects by the prophylactic administration of retosiban.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 4, 2017
    Inventor: Gordon Campbell Sinclair SMITH
  • Publication number: 20170119780
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: November 8, 2016
    Publication date: May 4, 2017
    Inventors: Kevin Wayne Kuntz, Richard Chesworth, Kenneth William Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah Kathleen Knutson, Timothy James Nelson Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Publication number: 20170119781
    Abstract: The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as BSC class II or IV kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.
    Type: Application
    Filed: December 19, 2016
    Publication date: May 4, 2017
    Applicants: Hoffmann-La Roche Inc., CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Susanne MEIER, Carsten BRUESEWITZ
  • Publication number: 20170119782
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventors: Liang Lu, Liangxing Wu, Bo Shen, Wenqing Yao
  • Publication number: 20170119783
    Abstract: A method for treating Alzheimer's Disease (AD) by administering an efficacious amount of artemisone. It is hypothesized that the treatment counters AD by inhibiting the production of the amyloid protein which has been implicated as a contributing factor to the onset of AD and the associated AD dementia and memory loss. Additionally, artemisone acts to reduce inflammation in the brain associated with AD by inhibiting tumor necrosis factor (TNF). Artemisone is a particularly useful AD treatment as it is able to cross the blood-brain barrier whereas many other TNF inhibitors are unable to do so. Artemisone may be administered via the following routes: subcutaneous, intravenous, intrathecal, intramuscular, intranasal, oral, transepidermal, parenteral, by inhalation, or intracerebroventricular.
    Type: Application
    Filed: August 16, 2016
    Publication date: May 4, 2017
    Inventor: Peter Parsonson
  • Publication number: 20170119784
    Abstract: The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
    Type: Application
    Filed: April 2, 2015
    Publication date: May 4, 2017
    Inventors: ARNAUD SINAN KARABOGA, VIOLETA ISABEL PEREZ-NUENO, MICHEL SOUCHET, DIDIER DECAUDIN
  • Publication number: 20170119785
    Abstract: The present disclosure relates generally to sol-gel polymer composites that comprise chitosan, a hydrophilic polymer, a gelation agent, and optional additional ingredients in a suitable medium. Advantageously, the sol-gel polymer composite can form a durable seal or strong solid in response to one or more physiological stimulus. The disclosure further relates to medical and veterinary uses of the composite, particularly, methods and delivery systems for reducing or preventing the incidence of a mammary disorder in a dairy animal. More particularly, the disclosure includes methods and sol-gel polymer composite compositions for creating a physical barrier on the teat surface or in the teat canal or cistern of a non-human animal for prophylactic treatment of mammary disorders such as mastitis wherein the sol-gel polymer creates a seal in response to one or more physiological stimulus.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Inventors: SUMITRA RAJAGOPALAN, WILMS BAILLE, PIOTR KUJAWA, Christopher A. Zook, Rebecca R. Quesnell, Dennis L. Huczek, Stephen L. Secreast, Laibin Luo, Tammy A. Sanders
  • Publication number: 20170119786
    Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: November 11, 2016
    Publication date: May 4, 2017
    Inventors: Douglas I. Buckley, Gregory Duke, Allan S. Wagman
  • Publication number: 20170119787
    Abstract: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.
    Type: Application
    Filed: November 15, 2016
    Publication date: May 4, 2017
    Inventors: Steven A. GOLDMAN, Fraser SIM
  • Publication number: 20170119788
    Abstract: Disclosed are compositions comprising topical corticosteroids, such as fluticasone and mometasone, and a biopolymer in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a penetration enhancer, a buffering agent, and water. The biopolymer comprises chitosan. The compositions disclosed herein are suitable for the treatment of dermatological conditions including but not limited to healing wounds and treatment of dermatitis.
    Type: Application
    Filed: December 2, 2016
    Publication date: May 4, 2017
    Inventors: Sular Subramaniam Vanangamudi, Srinivasan Murali, Srinivasan Madhavan
  • Publication number: 20170119789
    Abstract: Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising cellular senescence that is induced by the medical therapy.
    Type: Application
    Filed: March 22, 2016
    Publication date: May 4, 2017
    Inventors: Judith Campisi, Marco Demaria
  • Publication number: 20170119790
    Abstract: The present invention relates to therapeutic agents for the targeted delivery of an immunosuppressive agent to monocytes and/or monocyte-derived cells comprising a binding moiety with specificity for monocytes and/or monocyte-derived cells and an immunosuppressive agent. In one embodiment, the agent is a glucocorticoid-antibody conjugate. The invention also relates to methods, uses, kits and compositions comprising such agents.
    Type: Application
    Filed: December 1, 2016
    Publication date: May 4, 2017
    Inventors: Niels Jonas Heilskov Graversen, Pia Svendsen, Peter Astrup Christensen, Soren Kragh Moestrup, Holger Jon Moller, Gabriele Anton
  • Publication number: 20170119791
    Abstract: Disclosed are compositions comprising betamethasone, such as betamethasone dipropionate or betamethasone valerate, and a biopolymer in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a buffering agent, and water. The biopolymer comprises chitosan. The compositions disclosed herein are suitable for the treatment of dermatological conditions including but not limited to healing wounds and treatment of dermatitis.
    Type: Application
    Filed: December 2, 2016
    Publication date: May 4, 2017
    Inventors: Sular Subramaniam Vanangamudi, Srinivasan Murali, Srinivasan Madhavan
  • Publication number: 20170119792
    Abstract: Disclosed are compositions comprising topical corticosteroids, such as clobetasol propionate and halobetasol propionate, and a biopolymer in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a buffering agent, and water. The biopolymer comprises chitosan. The compositions disclosed herein are suitable for the treatment of dermatological conditions including but not limited to healing wounds and treatment of dermatitis.
    Type: Application
    Filed: December 2, 2016
    Publication date: May 4, 2017
    Inventors: Sulur Subramaniam Vanangamudi, Srinivasan Murali, Srinivasan Madhavan
  • Publication number: 20170119793
    Abstract: The invention described herein pertains to the treatment of infections arising in bones and/or joints. The invention described herein also pertains to the treatment of infections arising from implants and prostheses. Bone and joint infections (BJIs) represent a serious medical condition that, if untreated, can lead to complete loss or loss of use of bones or, joints in the patient, and even death. BJIs include many diseases, such as acute and chronic osteomyelitis, including pediatric osteomyelitis, septic arthritis, and others.
    Type: Application
    Filed: June 12, 2015
    Publication date: May 4, 2017
    Inventor: Prabhavathi FERNANDES
  • Publication number: 20170119794
    Abstract: Provided herein are methods of treating a variety of disorders related to fat accumulation in humans with pharmaceutical formulations containing deoxycholic acid.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Applicant: Kythera Biopharmaceuticals, Inc.
    Inventors: Frederick Beddingfield, Elisabeth Sandoval, Nancy Jorgesen, Serge Lichtsteiner, Paul Lizzul, Todd Gross, Christine Somogyi
  • Publication number: 20170119795
    Abstract: The present invention discloses fused triterpene compounds, represented by the compounds of Formula I (as described herein), processes for their preparation, pharmaceutical compositions comprising the said compounds, their use as retinoid-related orphan receptors gamma (ROR?) modulators and/or interleukin-17 (IL-17) inhibitors and methods for their use in the treatment of a disease or a disorder mediated by ROR? and/or IL-17.
    Type: Application
    Filed: June 24, 2015
    Publication date: May 4, 2017
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Rajiv SHARMA, Namdev Narayan BORHADE, Narayan Subhash CHAKOR, Hitesh Devchandbhai MISTRY
  • Publication number: 20170119796
    Abstract: Disclosed herein is a pharmaceutical composition, comprising: (a) spironolactone; (b) a xanthan gum; (c) an anti-foaming agent; (d) a preservative; (f) a dispersing agent; (g) a sweetening agent; (h) a flavoring agent; (i) optionally a buffer to maintain the pH of the pharmaceutical composition within a range described herein; and (j) a sufficient amount of a water vehicle.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Applicant: CMP Development LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Publication number: 20170119797
    Abstract: The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventors: Steven M. Kumiega, Thomas J. Carroll, Ashley L. Boldt, Paula M. Gibson, Robert J. Huzinec, Burton Douglas Brown, David M. Stumpf
  • Publication number: 20170119798
    Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
    Type: Application
    Filed: December 9, 2016
    Publication date: May 4, 2017
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Supritha Vakada, Rajeev Singh Raghuvanshi
  • Publication number: 20170119799
    Abstract: This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Inventors: Félix GRASES FREIXEDAS, Joan PERELLO BESTARD, Fernando TUR ESPINOSA, Antonia COSTA BAUZA, Rafael M. PRIETO ALMIRALL, Isabel GOMILA MUÑIZ
  • Publication number: 20170119800
    Abstract: The present invention relates to stable pharmaceutical compositions of fosaprepitant or a salt thereof in the form of ready-to-use or ready-to-dilute compositions suitable for parenteral administration.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 4, 2017
    Inventors: Geena Malhotra, Sarabjit Singh, Abhijit Jadhav
  • Publication number: 20170119801
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Inventor: Herriot Tabuteau